NME1 and breast cancer: Lastly, breast cancer patients with cyclin D1+ and nm23-H1+ reported pCR benefits of 45.8% (n=1) and 29.5% (n=2) than 29.4% (n=1) in cyclin D1− and 5.3% (n=2) in nm23-H1− breast cancer patients.